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Abstract
Background: Overgrowth syndromes are known as a heterogeneous group of conditions characterized by a
generalized or segmental, symmetric or asymmetric, overgrowth that may involve several tissues. These disorders,
which present a wide range of phenotypic variability, are often caused by mosaic somatic mutations in the genes
associated with the PI3K/AKT/mTOR cellular pathway, a signaling cascade that plays a key role in cellular growth.
Overgrowth syndromes are frequently misdiagnosed. Given that they are also associated to an increased oncologic
risk, it is important to distinguish the clinical characteristic of these disorders since the first months of life.
Case presentation: We report the case of a seven-year-old male child with macrocephaly and right
lateralized overgrowth, reported from birth. The patient arrived to our attention after an initial diagnosis
of isolated benign macrocephaly was formulated at the age of 12 months. Afterwards, the child presented
a moderate intellectual disability and pain episodes at right lower limb. We repeated a brain Magnetic Resonance
Imaging that revealed ventriculomegaly, cerebellar tonsillar ectopia, a markedly thick corpus callosum, and white
matter abnormalities. The diagnosis of segmental overgrowth syndrome was formulated according to the clinical
presentation and confirmed by the finding of the variant c.2740G > A in the gene PIK3CA presented in somatic
mosaicism.
Conclusions: Our patient is the first children with the c.2740G > A variant in PIK3CA gene reported in Italy. We underline
the importance of the genotype-phenotype correlation in the diagnostic process of overgrowth syndromes and emphasize
the strict correlation between the mutation c.2740G >A in the PIK3CA gene and the Megalencephaly-Capillary
Malformation syndrome phenotype.
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Background
Overgrowth syndromes (OSs) are known as a heteroge-
neous group of conditions characterized by a generalized or
segmental, symmetric or asymmetric, overgrowth that may
involve many tissues such as bones, muscles, adipose tissue,
skin and nerves. These disorders may manifest at birth or
develop in the early childhood and can be associated to an
increased oncologic risk [1]. The more frequent anomalies
associated with segmental OSs are hamartomas, epidermal
nevi, lymphovascular malformations, lipomatosis, hemihy-
pertrophy/hemihyperplasia (these terms have been recently
replaced with “lateralized overgrowth” [2]), polydactyly,
encephalic developmental anomalies, macrocephaly and
other skull abnormalities [1].
In the majority of cases, segmental OSs are caused by
mosaic somatic mutations in the genes associated with the
PI3K/AKT/mTOR cellular pathway, a signaling cascade
that plays a key role in cellular growth [3]. In mosaic
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diseases, the mutations occur during mitotic cell division,
producing two or more genetically distinct cell lineages
originating from a single zygote [4]. The wide range of
phenotypic variability of segmental OSs and their overlap-
ping features may be explained by the timing of the muta-
tion’s occurrence during the embryonic development, the
tissue localization of the mutation, the level of mosaicism
and the potential allelic heterogeneity [5].
Clinical CASE
A seven-and-a-half-year-old male child was sent to our
Pediatric Endocrinology Centre for macrocephaly and
right lateralized overgrowth, reported from birth.
Parents were not related and no noteworthy diseases were
reported in his family history. The pregnancy was charac-
terized by spontaneous abortion of the dizygotic twin at
16 gestational weeks. Fetal ultrasounds were normal. He
was born at 35 weeks of gestational age by an emergency
caesarean section for acute fetal suffering. Birth weight
was 3010 g (1.65 standard deviations [SD]), birth length
was 51 cm (2.45 SD) and birth occipito-frontal circumfer-
ence (OFC) was 36 cm (2.93 SD).
The perinatal period was characterized by hospitalization
because of the mild prematurity, neonatal jaundice treated
with phototherapy and the findings of hypotonia. In his first
months of life he presented a progressive increase of the
OFC and was submitted to brain Magnetic Resonance
Imaging (MRI) and to neurosurgical evaluation, which per-
mitted an initial diagnosis of isolated benign macrocephaly.
The MRI was repeated at the age of 2, revealing ventri-
culomegaly, Chiari Malformation type I and an arachnoid
left temporo-polar cyst. At neurological evaluation, he
presented a developmental delay characterized by an acqui-
sition of sitting position at 30 months of life and autono-
mous walking at 3 years of life and a speech delay with first
production of words after 2 years of age. Since he was
3 years old he has been suffering from pain episodes at
right lower limb unrelated to physical activity or other spe-
cific events, usually characterized by prolonged duration,
good response to paracetamol and associated to limb failure
and fall to the ground.
At our first physical examination his weight was
24.9 kg (0.54 SD), height 118.3 cm (− 1.42 SD) and OFC
60.5 cm (> 3 SD). He had several capillary malformations
on medial axis. His face presented two frontonasal hem-
angiomas, a hyperpigmented brownish stain on the fore-
head with telangiectasia, and two on flat hemangiomas
the trunk; furthermore, the patient had low-set ears,
teeth with serrated edges, diffuse muscular hypotonia,
joint hypermobility, and a fine and gross motor dys-
praxia associated to a mild intellectual disability. His
right lateralized overgrowth involved face, trunk and
limbs (mainly legs). In particular, he showed a mild
asymmetry of the face and of the facial mime with the
right side more represented, different length and diam-
eter of the legs (the right were 66 cm and 40 cm respect-
ively and the left one 63 cm and 36 cm) and of the
forearms, measured from elbow to the end of the middle
finger (the right were 29 cm and 14 cm respectively, the
left one 26 cm and 12 cm).
X-ray, ultrasounds and MRI of lower limbs were per-
formed confirming the asymmetry in length of the legs
and showing a musculature and a panniculus adiposus of
the right side more represented than the contralateral.
Echocardiogram and abdominal ultrasound were normal.
Brain MRI was repeated confirming previous findings of
ventriculomegaly, arachnoid left temporo-polar cyst, cere-
bellar tonsillar ectopia. Furthermore, it revealed a mark-
edly thick corpus callosum (mega-CC), abnormalities of
white matter, an area of polymicrogyria, and a pituitary
gland with a mild reduction in volume for age (Fig. 1).
The electroencephalography showed sporadic and isolated
paroxysmal abnormalities. The functional evaluation
permitted a diagnosis of mild intellectual disability,
attention-deficit, hyperactivity disorder and emotional dis-
turbance (Wechsler Intelligence Scale for Children-IV:
Total Intelligence Quotient 51).
On the basis of these clinical signs and symptoms we
hypothesized an OS and sent the patient to geneticists
for specific evaluation. Pediatric geneticists of the
Pediatric Department of MBBM Fundation, Monza,
Italy, confirmed our diagnostic suspicion and diagnosed
a segmental OS. Consequently, the child was submitted
to the molecular analysis of 21 selected genes involved
in the PI3K/AKT/mTOR pathway (PIK3R1, PIK3R2,
PIK3CA, PTEN, PDK1, PDK2, KRAS, AKT1, AKT2,
AKT3, RICTOR, MAPKAP1, MLST8, MTOR, IRS1,
GAB1, GAB2, THEM4, MAPK8IP1, PTPN11, RPTOR).
To identify causative mosaic somatic mutation on these
genes the genomic DeoxyriboNucleic Acid (DNA) was
extracted from cutaneous biopsy of affected tissue and
Targeted Next generation sequencing (NGS) was per-
formed. The pathogenic point mutation c.2740G >A
(pGly914Arg) in PIK3CA exon 18 was isolated in the ge-
nomic DNA of our patient. It was identified in heterozy-
gosity and was presented as somatic mosaic with a
frequency of 31.2%. The identified variant was verified by
Sanger sequencing.
Discussion and conclusions
Our patient is the first child with the c.2740G > A
(pGly914Arg) variant in PIK3CA gene reported in Italy
and the 19th case described in literature. The detection
of this somatic mutation confirmed our clinical suspi-
cion of segmental OS.
PIK3CA gene, localized on chromosome 3 in the
q26.32 position, encodes for the catalytic subunit p110α
of PI3K. When growth factors stimulate PI3K, its catalytic
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subunit p110α converts phosphatidylinositol 4,5-bispho-
sphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate
(PIP3) and permits activation of AKT protein and then
the activation of mTOR signalization pathway that in-
duces cellular proliferation [3]. Available functional studies
have demonstrated that several variants in p110α disrupt
the inactive conformation of PIK3 complex and maintain
the catalytic subunit in a high activity state [6].
Recently, segmental OSs caused by somatic activating
mutation of the gene PIK3CA were unified and collected
under the term of “PIK3CA-Related Overgrowth Spectrum
(PROS)”, stressing the importance of the genotype-pheno-
type correlation analysis in the diagnostic process of these
diseases [3] (Table 1). In particular, the c.2740G >A variant
found in our patient was already identified and was consid-
ered pathogenic in 18 patients with Megalencephaly-Capil-
lary Malformation-Polymicrogyria syndrome (MCAP) [7–
11]. MCAP was first described in 1997 [12, 13] and is
phenotypically characterized by involvement of the Central
Nervous System (CNS) and vascular anomalies [14]. In
further detail, the phenotype of MCAP is characterized
by a congenital or early postnatal megalencephaly, ven-
triculomegaly (that may lead to hydrocephalus),
progressive cerebellar tonsillar ectopia leading to Chiari
Malformation, and cortical brain abnormalities, such as
polymicrogyria and white matter abnormalities [15].
Secondary neurological symptoms, such as develop-
mental delay, ranging from mild to severe, hypotonia
(especially neonatal onset), seizures, autistic features,
and behavioral problems, such as unexplained irritabil-
ity, attention deficit, hyperactivity disorder, and obses-
sive compulsive disorder, are also included in clinical
presentation [15, 16]. Other clinical features associated
to this syndrome are vascular anomalies, especially
Fig. 1 Brain MRI: markedly thick corpus callosum and Chiari malformation type I (highlighted by the white arrow) represented in panel a;
abnormalities of white matter (highlighted by the black arrow) and arachnoid left temporo-polar cyst (highlighted by the asterisk) represented in
panel b; area of polymicrogyria in right parietal region (highlighted by the black triangles) represented in panel c
Table 1 PROS: PIK3CA-Related Overgrowth Spectrum
MCAP (megalencephaly-capillary malformations syndrome)
DMEG (dysplastic megalencephaly)
CLOVES (Congenital Lipomatous Overgrowth, Vascular Malformations,
Epidermal Nevi, Scoliosis/Skeletal and Spinal syndrome)
HHML (hemihyperplasia-multiple lipomatosis)
Fibroadipose hyperplasia or Overgrowth (FAO)
Klippel-Trenaunay Syndrome
Fibroadipose Infiltrating Lipomatosis, Seborrheic keratosis (SK), Benign
lichenoid keratosis (BLK), Epidermal nevi (EN)
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capillary malformations of midline face and body, distal
limb anomalies, syndactyly and polydactyly, connective
tissue dysplasia at variable degrees (skin hyperelasticity,
skin laxity, joint hypermobility, and thick subcutaneous
tissue), and mild focal or segmental somatic body over-
growth [16].
The diagnosis of MCAP syndrome could be established
in our patient according to the clinical criteria of MCAP
(Table 2), supported by the correlation between MCAP
phenotype and the point mutation c.2740G > A in
PIK3CA gene, already reported in literature [16]. Our pa-
tient, in fact, presented megalencephaly, Chiari malforma-
tion, ventriculomegaly, and white matter abnormalities at
brain MRI, capillary anomalies, developmental delay, and
right lateralized overgrowth. It is essential to emphasize
that lateralized overgrowth is a peculiar clinical sign of the
disease; however, it was not taken into consideration until
pediatric endocrinological evaluation at the age of 7. Al-
though there are no widely accepted criteria for defining
lateralized overgrowth as distinct from normal growth
variation in children [2], it is important to differentiate a
paraphysiological asymmetry in the body and a lateralized
overgrowth, as present in our patient, in order to obtain a
definitive diagnosis as soon as possible.
In PROS, an increase in the carcinogenic risk is also de-
scribed. Somatic mutations in PIK3CA are very similar to
those seen in many cancers, including glioblastoma and
colorectal, ovarian, breast, and hepatocellular carcinomas
[17]. Although malignancies have been reported with in-
ferior recurrence in MCAP than in patients with other
OSs, Wilms tumor, meningioma, and leukemia have been
reported in MCAP patients [16]. Only the results of
prospective studies will clarify the oncogenic risk of these
disorders. Meanwhile, it would be prudent to recommend
serial abdominal ultrasound every 3–4 months until the
age of 8 years and neurological monitoring and spinal
MRI scan in patients with truncal involvement, in order to
exclude the presence of major nerve neurofibromas or
vascular/lipomatous lesions [17]. Our patient did not
present a malignancy in early childhood, even if he was
not submitted to an adequate surveillance because of the
delayed diagnosis. Although all these signs and symptoms
may be correlated to MCAP, the diagnosis was achieved,
in fact, only at the age of 8 years old. Initially the Chiari
Malformation was misinterpreted as benign macrocephaly
and analogously, other typical features of the syndrome
identified at brain MRI, such as alteration of periventricu-
lar white matter, were considered at first evaluation as a
consequence of neonatal suffering.
In some cases of segmental OSs clinical diagnosis
might be difficult because the phenotypes have variable
expression and overlapping features, due to the mosai-
cism of the mutation. In fact, only few patients present
all the characteristic features described above [18]. In
particular, our patient presented as initial main pheno-
typic characteristic an isolated macrocephaly that needed
MRI and neurosurgical evaluation. This clinical sign
might be associated with different OSs related to
mutations of the PI3K/AKT/mTOR molecular pathway
besides MCAP, such as megalencephaly-polymicrogyria-
polydactyly-hydrocephalus syndrome (MPPH) [11], and
PTEN related diseases, such as Cowden disease,
Bannayan syndrome, and Proteus syndrome [19], that
may be associated with different degree of developmental
delay. This is precisely why it is necessary to have molecu-
lar diagnosis. Targeted next generation is the preferred
method for molecular diagnosis of segmental OSs because
it offers a much deeper sequencing coverage and allows
the detection of low-level mosaicism [8]. In our case the
genomic DNA was extracted from fibroblasts obtained
from a biopsy of cutaneous affected tissue, usually consi-
dered the best sample for the molecular diagnosis of seg-
mental OSs [16], when suspecting a mosaic somatic
mutation. In fact, the mosaicism levels detected in blood
samples are considerably lower compared to those seen in
affected tissues [11].
For affected patients and their countless clinical prob-
lems the therapeutic approach must be as wide and multi-
disciplinary as possible. A specific treatment does not
exist yet and until recently surgical debulking, orthopedic
procedures, and vascular interventional techniques have
been the only treatments available for patients with
Table 2 Diagnostic Criteria for MCAP: core feature (1) plus either two or three core features
Core features Supportive features Secondary features
(1) Early overgrowth (brain > somatic tissue)
progressive megalencephaly
Selective brain overgrowth (ventriculomegaly,
cerebellar tonsillar ectopia, abnormally thick cospus
callosum); congenital somatic overgrowth, somatic or
cranial asymmetry
Hypotonia
Developmental delay
Seizures
(2) Developmental vascular disorders capillary
malformations (midline face and body)
Infantile hemangiomas, venous aneurysms, aberrant
vasculature
(3) Distal limb anomalies (syndactily) Polydactyly, Sandal-gap toes
(4) Cortical brain malformations (polymicrogyria)
(5) Connective tissue dysplasia (skin hyperelasticity,
joint ipermobility, thick doughy subcutaneous tissue)
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segmental OSs [19]. Nevertheless, in more recent years
many clinical trials have been initiated utilizing small mol-
ecule inhibitors of the PI3K signaling network, previously
studied in oncology drug development area [20]. The re-
sults of these studies appear promising and underline once
again the value of the molecular analysis for a proper
diagnosis.
In conclusion, we underline the strict correlation
between MCAP phenotype and the pathogenic mutation
c.2740G > A in the PIK3CA gene. Therefore, we recom-
mend physicians to suspect a segmental OS in general,
and a MCAP in particular, in presence of generalized or
segmental overgrowth, overall if associated to megalen-
cephaly and other brain MRI anomalies, developmental
delay, vascular malformations and connective tissue dys-
plasia. In presence of these clinical signs and symptoms
it is mandatory for a pediatrician to send the patient for
a genetic evaluation at an early stage. In relation to gen-
etic indication, they should moreover submit the patient
to a molecular analysis in order to reach the appropriate
diagnosis and to establish the more correct follow up
and treatment.
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